Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medical Access Program for Ifinatamab Deruxtecan (I-DXd, DS-7300a)

NCT07535359 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT07535359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07535359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medical Access Program for Ifinatamab Deruxtecan (I-DXd, DS-7300a)
Lead sponsor
Daiichi Sankyo
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer, sclc